Multinational Real-World Practice Patterns in the Use of Antithrombotic Therapy Among Patients on Hemodialysis and Peritoneal Dialysis
Antithrombotic drugs are infrequently prescribed and often discontinued in patients receiving HD or PD. With major bleeding event rates high among antithrombotic users, new strategies are needed to optimize the risks and benefits of antithrombotic agents in the dialysis setting.
Authors
- Mohammed Al Ghonaim
- Pablo Ureña‐Torres (ORCID: https://orcid.org/0000-0001-6757-1906)
- Murilo Guedes (ORCID: https://orcid.org/0000-0002-3495-852X)
- Junhui Zhao
- Angelo Karaboyas (ORCID: https://orcid.org/0000-0001-8846-5360)
- Lori D. Bash (ORCID: https://orcid.org/0000-0002-6036-2498)
- Irina Barash (ORCID: https://orcid.org/0000-0002-0358-6591)
- Catelyn Coyle
- Marc P. Bonaca (ORCID: https://orcid.org/0000-0002-9860-3584)
- David Johnson (ORCID: https://orcid.org/0000-0002-5667-056X)
- Calvin Andrews
- Xuehua Ke
- Pietro Manuel Ferraro
- Dena Rosen Ramey (ORCID: https://orcid.org/0000-0002-2238-2930)
- G. Brandon Atkins
- Roberto Pecoits-Filho
Institutions
- University of Verona (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Université Paris Cité (FR)
- King Saud Medical City (SA)
- Princess Alexandra Hospital (AU)
- King Saud University (SA)
- Arbor Research Collaborative for Health (US)
- Institut Supérieur de Mécanique de Paris (FR)
- University of Colorado Denver (US)
- Stanford University (US)
Publication Details
- Journal
- Kidney Medicine
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1016/j.xkme.2025.101211
- Primary Topic
- Dialysis and Renal Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00